May. 5, 2014
BeiGene, a Beijing-based biopharma company founded in 2010, announced on May 5, 2014 that it will receive a $5 million milestone payment from Merck Serono, which in-licensed ex-China rights to BeiGene’s second-generation BRAF inhibitor last year. In December, BeiGene began enrolling patients in a China Phase I clinical trial of BGB-283 in cancer patients with BRAF or KRAS mutations. The deal for BGB-283, which is worth up to $233 million, is one of two cancer drug collaborations established between the two companies.